Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Withdrawn before enrolling · Phase 1

Conditions studied: Melanoma

In brief

This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma. However, the combination of these two drugs has not been studied. In this trial the investigators will determine the maximum dose of the drug combination to be administered to patients with advanced unresectable or metastatic melanoma and examine the safety profile of the drug combination.

Key facts

Study ID
NCT02300935
Run by
SCRI Development Innovations, LLC
People needed
0
Starts
2015-12-01
Expected to finish
2016-01-20
Last updated by the study team
2019-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.